Statin Therapy Induces Gut Leakage and Neuromuscular Disjunction in Patients With Chronic Heart Failure

Supplemental Digital Content is Available in the Text. Abstract: Statins are commonly used to limit the risk of cardiovascular diseases, including ischemic heart attack and stroke. However, treatment often leads to myopathy and muscle weakness. Therefore, a better understanding of underlying pathomechanism is needed to improve the clinical outcomes. Here, we assessed the physical performance, including handgrip strength (HGS), gait speed (GS), and short physical performance battery, in 172 patients diagnosed with chronic heart failure (CHF) treated with (n = 50) or without (n = 122) statin and 59 controls. The plasma biomarkers, including sarcopenia marker C-terminal agrin fragment-22 (CAF22), intestinal barrier integrity marker zonulin, and C-reactive protein (CRP), were measured and correlated with the physical performance of patients. The HGS, short physical performance battery scores, and GS were significantly compromised in patients with CHF versus controls. Irrespective of etiology, significant elevation of plasma CAF22, zonulin, and CRP was observed in patients with CHF. There were strong inverse correlations of CAF22 with HGS (r2 = 0.34, P < 0.0001), short physical performance battery scores (r2 = 0.08, P = 0.0001), and GS (r2 = 0.143, P < 0.0001). Strikingly, CAF22 and zonulin were positively correlated with each other (r2 = 0.10, P = 0.0002) and with the level of CRP in patients with CHF. Further investigations revealed a significant induction of CAF22, zonulin, and CRP in patients with CHF taking statin versus nonstatin group. Consistently, HGS and GS were significantly lower in the statin versus nonstatin CHF patients' group. Collectively, statin therapy adversely affects the neuromuscular junction and intestinal barrier, which potentially induces systemic inflammation and physical disability in patients with CHF. Further prospective confirmation of the findings is required in a well-controlled study.

[1]  R. Qaisar,et al.  Plasma Galectin-3 and H-FABP correlate with poor physical performance in patients with congestive heart failure , 2023, Experimental biology and medicine.

[2]  R. Qaisar,et al.  Plasma zonulin correlates with cardiac dysfunction and poor physical performance in patients with chronic heart failure. , 2022, Life sciences.

[3]  M. J. Pons,et al.  Zonulin, a marker of gut permeability, is associated with mortality in a cohort of hospitalised peruvian COVID-19 patients , 2022, Frontiers in Cellular and Infection Microbiology.

[4]  J. Killian,et al.  Activities of Daily Living and Outcomes in Patients with Advanced Heart Failure. , 2022, The American journal of medicine.

[5]  R. Qaisar,et al.  Elevated plasma zonulin and CAF22 are correlated with sarcopenia and functional dependency at various stages of Alzheimer’s diseases , 2022, Neuroscience Research.

[6]  B. Ding,et al.  Intestinal Permeability Associated with the Loss of Skeletal Muscle Strength in Middle-Aged and Older Adults in Rural Area of Beijing, China , 2022, Healthcare.

[7]  R. Qaisar,et al.  A multistrain probiotic reduces sarcopenia by modulating Wnt signaling biomarkers in patients with chronic heart failure. , 2022, Journal of Cardiology.

[8]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[9]  Weiqing Wang,et al.  The Intestinal Effect of Atorvastatin: Akkermansia muciniphila and Barrier Function , 2022, Frontiers in Microbiology.

[10]  R. Halwani,et al.  SARS‐CoV‐2 infection induces soluble platelet activation markers and PAI‐1 in the early moderate stage of COVID‐19 , 2022, bioRxiv.

[11]  M. D’Amato,et al.  Intestinal Barrier and Permeability in Health, Obesity and NAFLD , 2021, Biomedicines.

[12]  R. Qaisar,et al.  Intestinal permeability marker zonulin as a predictor of sarcopenia in chronic obstructive pulmonary disease. , 2021, Respiratory medicine.

[13]  R. Qaisar,et al.  Prediction of Sarcopenia Using Multiple Biomarkers of Neuromuscular Junction Degeneration in Chronic Obstructive Pulmonary Disease , 2021, Journal of personalized medicine.

[14]  Jonathan P. Jacobs,et al.  Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome , 2021, Frontiers in Endocrinology.

[15]  M. Bona,et al.  Intestinal barrier function in obesity with or without metabolic syndrome: a systematic review protocol , 2021, BMJ Open.

[16]  Lin Bai,et al.  Simvastatin accelerated motoneurons death in SOD1G93A mice through inhibiting Rab7-mediated maturation of late autophagic vacuoles , 2021, Cell Death & Disease.

[17]  Amber Price,et al.  Dysbiosis and Intestinal Barrier Dysfunction in Pediatric Congenital Heart Disease Is Exacerbated Following Cardiopulmonary Bypass , 2021, JACC. Basic to translational science.

[18]  C. Lewis,et al.  Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. , 2020, American journal of physiology. Heart and circulatory physiology.

[19]  M. Jackson,et al.  Neuron‐specific deletion of CuZnSOD leads to an advanced sarcopenic phenotype in older mice , 2020, Aging cell.

[20]  J. Springer,et al.  Muscle Wasting and Sarcopenia in Heart Failure—The Current State of Science , 2020, International journal of molecular sciences.

[21]  R. Qaisar,et al.  Plasma CAF22 Levels as a Useful Predictor of Muscle Health in Patients with Chronic Obstructive Pulmonary Disease , 2020, Biology.

[22]  C. Deaton,et al.  Heart failure disease management: a systematic review of effectiveness in heart failure with preserved ejection fraction , 2020, ESC heart failure.

[23]  M. Pirmohamed,et al.  Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components , 2019, Journal of clinical medicine.

[24]  D. Tilley,et al.  Nicotinamide riboside kinase-2 alleviates ischemia-induced heart failure through P38 signaling. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[25]  Heetae Lee,et al.  Alterations in Gut Microbiota by Statin Therapy and Possible Intermediate Effects on Hyperglycemia and Hyperlipidemia , 2019, Front. Microbiol..

[26]  H. Westerblad,et al.  A Mechanism for Statin-Induced Susceptibility to Myopathy , 2019, JACC. Basic to translational science.

[27]  M. Camilleri Leaky gut: mechanisms, measurement and clinical implications in humans , 2019, Gut.

[28]  M. Harris-Love,et al.  The Influence of Upper and Lower Extremity Strength on Performance-Based Sarcopenia Assessment Tests , 2018, Journal of functional morphology and kinesiology.

[29]  Davor Milicic,et al.  Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.

[30]  Benjamin Geiger,et al.  Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection , 2018, Science.

[31]  G. Fonarow,et al.  Statins and the Prevention of Heart Disease. , 2017, JAMA cardiology.

[32]  D. Gutekunst,et al.  Isokinetic Torque Timing Parameters and Ceramides as Markers of Muscle Dysfunction in Systolic Heart Failure. , 2016, Journal of cardiac failure.

[33]  R. Aquilani,et al.  Pathogenic Gut Flora in Patients With Chronic Heart Failure. , 2016, JACC. Heart failure.

[34]  S. Anker,et al.  Detection of muscle wasting in patients with chronic heart failure using C‐terminal agrin fragment: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF) , 2015, European journal of heart failure.

[35]  Jibin Zhou,et al.  Cardiomyocyte-specific deletion of Gsk3α mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. , 2014, Journal of the American College of Cardiology.

[36]  M. T. Ryan,et al.  Supplemental Digital Content , 2013 .

[37]  R. Saxena,et al.  Phenotypic and molecular characterisation of type 3 von Willebrand disease in a cohort of Indian patients , 2013, Thrombosis and Haemostasis.

[38]  N. Maragakis,et al.  Selected statins produce rapid spinal motor neuron loss in vitro , 2012, BMC Musculoskeletal Disorders.

[39]  J. Auwerx,et al.  Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. , 2012, European heart journal.

[40]  M. Francolini,et al.  Specific proteolytic cleavage of agrin regulates maturation of the neuromuscular junction , 2010, Journal of Cell Science.

[41]  S. Lines,et al.  Dipstick test for myoglobinuria , 2008, BMJ : British Medical Journal.

[42]  P. Sonderegger,et al.  Neurotrypsin cleaves agrin locally at the synapse , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  P. Sirvent,et al.  Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. , 2005, Biochemical and biophysical research communications.

[44]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[45]  R. Qaisar,et al.  Circulating Biomarkers of Handgrip Strength and Lung Function in Chronic Obstructive Pulmonary Disease , 2020 .

[46]  K. Glas,et al.  Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.